Search Results

Elucida Oncology announced that Geno Germano, CEO and President of Elucida Oncology, will present at the Evercore ISI 2024 Emerging Biotech Conference.

Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced that Geno Germano, CEO and President of Elucida Oncology, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco.

Elucida Oncology announced that Ramzi Benamar, a seasoned financial leader with a proven track record in the life sciences industry, has been appointed as Chief Financial Officer, effective September 1, 2023.

Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today an abstract featuring ELU001, its lead C’Dot Drug Conjugate (CDC) clinical candidate, has been accepted for poster presentation at the ESMO Congress 2023 being held in Madrid, Spain from October 20-24, 2023.

Elucida Oncology announced today that new data have been presented from its recently completed dose escalation/safety phase of its first-in-human Phase 1/2 clinical trial evaluating ELU001, its lead C’Dot drug conjugate (CDC) clinical candidate, at the ESMO Congress 2023 being held in Madrid, Spain.

Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that the first patient has been treated with ELU001, its proprietary folate receptor alpha (FRα)-targeted C’Dot drug conjugate (CDC), in one of three Tumor Group Expansion Cohorts in its Phase 1/2 trial.

Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that two abstracts featuring ELU001, its lead C’Dot Drug Conjugate (CDC) clinical candidate, have been accepted for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, to be held April 14-19, in Orlando, FL.

Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced that management will participate at the 41st Annual J.P. Morgan Healthcare Conference taking place in San Francisco, California.

Elucida Oncology announced that Geno Germano, CEO and President of Elucida Oncology, will present at the Bank of America 2022 Healthcare Conference in Las Vegas, NV on Tuesday, May 10, at 4:40pm PST.

Primarily known as an immunology and neuroscience company, AbbVie wanted to put the biopharma world on notice during its J.P. Morgan presentation: its oncology portfolio is underappreciated. This week, the Illinois-based company dove into the sizzling PD-1/VEGF space with a licensing deal with China-based RemeGen.